Rationale: Preoperative identification of patients at risk for lymph node metastasis (LNM) is challenging in endometrial cancer (EC). Therefore, a Bayesian network model called ENDORISK was developed and validated in three external cohorts to improve preoperative risk stratification. The next step is to implement and evaluate whether use of the model improves daily clinical practice. Objective: The ENDORISK implementation (ENDORISK-I) study aims to prospectively evaluate whether implementation of ENDORISK in daily clinical practice improves preoperative risk stratification. Study design: A stepped wedge non inferiority study in which two oncology regions will consecutively start implementation of ENDORISK with one year interval. The ENDORISK model will be filled in and used in preoperative treatment counselling. Results will be compared to current standard clinical care which is prospectively evaluated in both regions since March 2022 in the 'evaluation of care in endometrial cancer' study (2021-7400). Study population: all consecutive patients recently diagnosed with early stage EC who are eligible for surgical treatment, who understand Dutch and are able to fill in a digital or paper questionnaire can be included. Main study parameters/endpoints: The ENDORISK implementation (ENDORISK-I) study aims to prospectively evaluate implementation of ENDORISK in daily clinical practice by investigating: * The proportion of identified LNM in patients with lymph node staging (positive predictive value (PPV)) compared to standard care * Proportion of patients who decide to have lymph node status assessed in ENDORISK care compared to standard care * Preoperative information provision for patients and shared-decision making with the use of ENDORISK compared to standard care * Patients' disease- specific-, overall survival, and health-related quality of life compared to standard care * Patients' and doctors' use of and experiences with the ENDORISK-model * Impact of ENDORISK on regional care costs
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
735
The intervention group are patients receiving a personalized risk on lymph node metastases as predicted by the ENDORISK model, they also receive a treatment plan (hysterectomy + bilateral salpingo-oophorectomy with or without lymph node surgery) based on this personalized risk.
Rijnstate
Arnhem, Gelderland, Netherlands
NOT_YET_RECRUITINGSlingeland Hospital
Doetinchem, Gelderland, Netherlands
NOT_YET_RECRUITINGGelderse Vallei
Ede, Gelderland, Netherlands
NOT_YET_RECRUITINGRadboudumc
Nijmegen, Gelderland, Netherlands
NOT_YET_RECRUITINGCanisius Wilhelmina Ziekenhuis (CWZ)
Nijmegen, Gelderland, Netherlands
NOT_YET_RECRUITINGStreekziekenhuis Koningin Beatrix
Winterswijk, Gelderland, Netherlands
NOT_YET_RECRUITINGJeroen Bosch Hospital
's-Hertogenbosch, North Brabant, Netherlands
RECRUITINGAmphia
Breda, North Brabant, Netherlands
RECRUITINGCatharina Hospital
Eindhoven, North Brabant, Netherlands
RECRUITINGSt. Anna Hospital
Geldrop, North Brabant, Netherlands
RECRUITING...and 4 more locations
Proportion of patients who decide to have lymph node status assessed in ENDORISK care compared to standard care.
Time frame: from enrolment to surgery
Proportion of patients with lymph node metastases within patients undergoing lymph node staging (the positive predictive value) in ENDORISK care
The lymph node metastases in patients undergoing lymph node staging will be determined by pathology report on the surgical specimen. The positive predicting value will be compared to the positive predictive value of standard care.
Time frame: From enrolment to time of surgery
Preoperative information provision for patients and shared-decision making with the use of ENDORISK compared to standard care, measured by questionnaires.
Information provision score: Questionnaire EORTC Quality of Life Questionnaire (QLQ)-INFO25 with additional questions specific to ENDORISK use. Shared-decision making score: Shared Decision Making Questionnaire SDM-Q-9 with additional questions specific to ENDORISK use
Time frame: From enrolment to 12 weeks post-operatively
Patients' 5-year disease- specific-, overall survival (DSS, OS), compared to standard care;
Time frame: from enrolment to 5-year post surgery
Health related quality of life (HRQoL) compared to standard care
as measured by questionnaire: EORTC Quality of life questionnaire (QLQ) -C30
Time frame: 12 weeks after primary surgery
Health-related quality of life (HRQoL) compared to standard care
as measured by questionnaire: EORTC QLQ-C30
Time frame: 12 months after primary surgery
Treatment-related morbidity compared to standard care
As measured by questionnaire: EORTC QLQ- Endometrial cancer (EN) 24
Time frame: 12 weeks after primary surgery
Treatment related morbidity compared to standard care
As measured by questionnaire: EORTC QLQ-EN24 and questionnaires about lymphoedema: EORTC IL76 \& Lymphoedema quality of Life (LYMQOL)
Time frame: 12 months after primary surgery
Clinicians' experiences with ENDORISK care
Questionnaire at baseline
Time frame: at baseline
Clinicians' experiences with ENDORISK care
Questionnaire at 9 months
Time frame: 9 months after start of inclusions
Clinicians' experiences with ENDORISK care
Questionnaire at 18 months
Time frame: 18 months after start of inclusions
Clinicians' experiences with ENDORISK care
In depth interviews with a sample of participating clinicians to evaluate user experiences.
Time frame: Within 1 year of start of the inclusion period in their hospital.
Impact of ENDORISK on regional care costs
Time frame: from enrolment to the end of inclusions
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.